A pilot study of rituximab in patients with recurrent, classic Hodgkin disease-Reference-Cited by-同舟云学术

A pilot study of rituximab in patients with recurrent, classic Hodgkin disease

Published:2003-07-02 Issue:2 Volume:98 Page:310-314
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Younes Anas,Romaguera Jorge,Hagemeister Frederick,McLaughlin Peter,Rodriguez Maria Alma,Fiumara Paolo,Goy Andre,Jeha Sima,Manning John T.,Jones Dan,Abruzzo Lynne V.,Medeiros L. Jeffrey

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference27 articles.

1. Reed-Sternberg Cells and the TNF Family of Receptors/Ligands

2. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy

3. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines

4. Functional expression of receptor activator of nuclear factor κB in Hodgkin disease cell lines

5. CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies

Cited by 147 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical relevance and therapeutic implications of CD20 expression in Hodgkin's lymphoma;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

2. CAR-T Cell Therapy for Classical Hodgkin Lymphoma;HemaSphere;2023-11-16

3. Classical Hodgkin Lymphoma: From Past to Future—A Comprehensive Review of Pathophysiology and Therapeutic Advances;International Journal of Molecular Sciences;2023-06-13

4. Immunotherapy for Hodgkin lymphoma: From monoclonal antibodies to chimeric antigen receptor T-cell therapy;Critical Reviews in Oncology/Hematology;2023-02

5. Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin’s lymphoma: a phase II, non-randomized controlled trial;Journal for ImmunoTherapy of Cancer;2022-05